Home > GAMMAGARD Products > GAMMAGARD LIQUID IV > Safety Profile

Safety Profile
GAMMAGARD LIQUID - IV Administration

Protecting life's moments with an established safety profile1,a

In the intravenous (IV) administration of GAMMAGARD LIQUID clinical study:

  • Adverse reactions with a frequency of ≥5% were: headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema, peripheral, pruritis, and cardiac murmur

  • In this clinical study, fifteen adverse reactions in 8 subjects were serious. Of these, two serious reactions (two episodes of aseptic meningitis in one patient) were deemed to be possibly related to the infusion of GAMMAGARD LIQUID

Adverse reactions occurring in ≥5% of subjects in the intravenous clinical studya

aAdverse reaction is defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period.

Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.

  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Infusion Training Get training support from our Nurse
    Advocates on intravenous and subcutaneous administration of GAMMAGARD LIQUID.

    Call 1-855-250-5111 to talk to a
    Nurse Advocate
  • Insurance Assistance For access to experts who can provide expedited benefits verification and other insurance coverage resources, call 1-855-250-5111.
Error processing SSI file